Cellular implant therapy - MicroIslet

Drug Profile

Cellular implant therapy - MicroIslet

Alternative Names: Microencapsulated porcine islets for implantation - MicroIslet; MicroIslet-P

Latest Information Update: 14 Jul 2008

Price : $50

At a glance

  • Originator Duke University
  • Developer Duke University; MicroIslet; The Scripps Research Institute; University of California, Davis
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Cell replacements; Insulin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 03 Jul 2008 Interim pharmacodynamics & adverse events data from preclinical trials in rodents and primates with Diabetes released by MicroIslet
  • 17 Sep 2007 Preclinical development is ongoing
  • 11 Aug 2006 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top